International Preliminary Examination

International Preliminary Examination (IPE) is an optional second examination stage available under the Patent Cooperation Treaty (PCT): THE PCT STRUCTURE: Chapter I — International Application and International Search: PCT application is filed; International Searching Authority (ISA) performs prior art search; Written Opinion of ISA (WO-ISA) issued; International Publication at 18 months; Chapter II — International Preliminary Examination: optional; invoked by filing a Demand for International Preliminary Examination; conducted by the International Preliminary Examining Authority (IPEA); results in an International Preliminary Report on Patentability (IPRP Chapter II); WHY REQUEST CHAPTER II: (a) MORE TIME: in countries that use the Chapter II deadline, national phase entry is extended from 20 months to 30 months from priority (though most countries now allow 30 months under Chapter I); (b) INTERACTIVITY: Chapter II allows the applicant to amend claims (Article 34 amendments) and respond to Written Opinions before the IPRP is issued; the applicant can have a dialogue with the IPEA examiner; (c) FAVORABLE IPRP: a favorable IPRP Chapter II opinion (finding novelty, inventive step, and industrial applicability) can be used strategically in national phase prosecutions to encourage national offices to allow the application; (d) PROSECUTION PREVIEW: if the IPRP is unfavorable, the applicant gets advance notice of the objections that national offices will likely raise — time to develop stronger arguments; WHEN IPE IS MOST VALUABLE: large international programs where strategy before multiple national offices is important; cases where the WO-ISA was negative and the applicant has strong amendments or arguments to make; technologies where the ISA's opinion may not align with leading national offices.

Filing a Demand invokes Chapter II and initiates the IPEA process: ELIGIBILITY: any PCT applicant can file a Demand; the applicant must have the right to be examined by the chosen IPEA (usually must be a resident/national of a country whose national office is competent for the IPEA, or any competent IPEA if none is specifically designated); DEADLINE FOR FILING DEMAND: the later of: 3 months from the date of transmittal of the ISA Written Opinion (WO-ISA); or 22 months from the priority date; THE DEMAND FORM (PCT/IPEA/401): identifies the IPEA; identifies the applicants; may identify claims to be examined; IPEA SELECTION: the IPEA must be competent for the applicant; competency depends on the applicant's nationality/residency and the rules of the IPEA; IPEA examples: USPTO IPEA (for US national phase applicants); EPO IPEA; KIPO IPEA (Korean IP Office); JPO IPEA; most major patent offices are ISAs and IPEAs; ARTICLE 34 AMENDMENTS: when filing the Demand, the applicant may file Article 34 claim amendments; these amendments are the basis for examination in Chapter II; amendments must not add new matter beyond the original disclosure; strategy: amend claims to overcome the ISA's prior art objections identified in the WO-ISA; narrow independently on each objection; add distinguishing features; FEES: international preliminary examination fee (varies by IPEA); handling fee; for USPTO IPEA: approximately $800-$2,000 depending on claim count; EXAMINATION TIMELINE: IPEA will issue a Written Opinion (IPEA WO); applicant has at least one opportunity to respond; IPRP Chapter II issued no later than 28 months from priority date; after IPRP is issued, national phase entry proceeds.

The International Preliminary Report on Patentability (IPRP) Chapter II is the final written assessment from the IPEA: CONTENT OF THE IPRP CHAPTER II: for each claim examined: whether the claim appears to meet the PCT criteria for patentability: novelty (Art. 33(2)); inventive step (Art. 33(3)); industrial applicability (Art. 33(4)); where the claim appears patentable, positive statement; where not, explanation of deficiencies and citation of prior art; IPRP IS NOT BINDING: the IPRP is explicitly advisory — it is not binding on national offices; national offices are free to conduct their own examination and reach different conclusions; HOWEVER, IPRP HAS STRATEGIC VALUE: FAVORABLE IPRP: signals to national offices that an international examiner found the claims patentable; some national offices (particularly smaller offices without large examination resources) give significant weight to a favorable IPRP; may accelerate examination in some national offices; UNFAVORABLE IPRP: reveals the objections applicant will face nationally; applicant can prepare stronger arguments or plan amendments for national phase; may allow filing more targeted claims in each national phase; APPLICANT-FRIENDLY OFFICES: offices in many developing countries rely heavily on IPRP; a favorable IPRP in these countries can make the difference between allowance and rejection; IPRP CHAPTER II vs. IPRP CHAPTER I: all PCT applications receive an IPRP Chapter I (based on the ISA WO) — it is automatically transmitted to national offices without any action by the applicant; only if a Demand is filed does the applicant get an IPRP Chapter II — more detailed, based on examiner dialogue; NATIONAL PHASE TIMING: whether or not Chapter II was filed, the national phase entry deadline is 30 months from priority in most countries (this is set by PCT Rule 22bis, adopted broadly); a few countries maintain the 20-month deadline for Chapter I entries.

Article 34 amendments are the key tool for shaping claims before the IPRP is issued: AUTHORITY FOR AMENDMENTS: PCT Article 34(2)(b): applicant has a right to amend claims (and description/drawings) once during Chapter II examination; additional amendments may be made with permission of the IPEA; WHAT CAN BE AMENDED: claims: most commonly amended; description: can be amended to provide support for amended claims; drawings: less frequently amended; WHAT CANNOT BE ADDED: no new matter: amendments cannot introduce matter not supported by the original disclosure; same standard as in national prosecution; STRATEGY FOR ARTICLE 34 AMENDMENTS: amend when the WO-ISA identifies specific prior art that can be distinguished by adding claim limitations; don't over-narrow: each limitation added creates a potential design-around for infringers and estoppel in national prosecution; EXAMPLE STRATEGY: WO-ISA identifies a reference (Reference A) showing elements 1, 2, and 3 of the claim; applicant adds limitation 4 (disclosed in specification but not in Reference A) to distinguish; if IPEA finds limitation 4 novel, inventive step established; favorable IPRP issues on narrowed claims; applicant enters national phase with favorable IPRP and arguments prepared; CLAIM FORMAT: Article 34 amendments should comply with PCT rule on claim format; independent claims should be broadest defensible scope given known prior art; DIFFERENT CLAIMS FOR DIFFERENT COUNTRIES: after Chapter II, the applicant can file DIFFERENT claims in each national phase; use Article 34 amendments to establish favorable IPRP on one set of claims; in specific national phases (e.g., US continuation strategy, EPO), file claims tailored to that jurisdiction's law; this is a key strategic advantage of the PCT system.

The decision to file a Chapter II Demand involves cost-benefit analysis: COSTS OF CHAPTER II: IPEA filing fees: $800-$2,000+ (varies by IPEA and claim count); attorney time to prepare Article 34 amendments and respond to Written Opinions: $2,000-$10,000+; TOTAL ADDITIONAL COST: $3,000-$15,000 for a typical Chapter II proceeding; BENEFITS OF CHAPTER II: FAVORABLE IPRP: in a large international program (10+ countries), a favorable IPRP can reduce prosecution costs in multiple national offices; if each national office is persuaded by the favorable IPRP, the savings per country (even $1,000-$5,000 in reduced prosecution) can quickly outweigh the Chapter II cost; PROSECUTION PREVIEW: even an unfavorable IPRP has value — knowing the objections before national phase entry allows preparation; can save costs by narrowing the national phase program to only the most commercially important countries; TIME TO REFINE: the 28-month window before IPRP issues gives applicant time to better understand commercial value and adjust national phase filing decisions; WHEN IT IS LIKELY WORTH IT: large international program (8+ countries); borderline patentability case where a favorable IPRP will meaningfully help; strong amendments can be made to distinguish the WO-ISA prior art; commercial importance of the application is high; WHEN IT MAY NOT BE WORTH IT: application only filing in 1-3 countries (Chapter II cost exceeds national prosecution savings); ISA opinion was favorable (Chapter I IPRP will also be favorable); cost-conscious startup limiting spend to only most critical markets; ALTERNATIVES TO CHAPTER II: PPH (Patent Prosecution Highway): request fast-track examination in national phase based on allowance in another national office; PCT-PPH: use ISA WO as basis for PPH request in national phase; no additional fee; can achieve similar benefit to favorable IPRP in offices that participate in PPH.